Alzinova AB (publ) (“Alzinova” or the “Company”) today announces that the Company’s scientific article presenting clinical results from ALZ-101 has now been published online in the peer-reviewed journal Alzheimer’s Research & Therapy. The publication makes the results available to the international scientific community and constitutes an important external validation of the Company’s clinical development program.
The article, entitled “Safety, Tolerability and Immunogenicity of Vaccine ALZ-101 in Patients with Early Alzheimer’s Disease: Randomised, Controlled Trial”, has now been published in the peer-reviewed journal Alzheimer’s Research & Therapy. The article presents the clinical results from Alzinova’s Phase 1b study of ALZ-101, a therapeutic vaccine candidate targeting toxic amyloid-beta oligomers in Alzheimer’s disease.
The publication includes an in-depth review of the study data, including analyses of primary and secondary endpoints as well as exploratory endpoints highlighting the potential disease-modifying properties of ALZ-101. The results demonstrate a favorable safety and tolerability profile together with induction of a specific immune response, collectively supporting the continued clinical development of ALZ-101.
The publication means that Alzinova’s clinical results are now available to the international scientific community and simultaneously represent an important external scientific validation of the Company’s development program. Visibility in an internationally established scientific journal also strengthens Alzinova’s position in ongoing discussions with potential partners and other strategic stakeholders within the field.
Supported by the positive clinical results, Alzinova continues its preparations for the next stage of development for ALZ-101. The Company is planning a Phase II study focused on further evaluating clinical efficacy, biomarkers and dosing regimen in patients with early Alzheimer’s disease, with the ambition to initiate the study around year-end. In parallel, the Company continues to expand its international network and establish new strategic collaborations.
The article has been published online with open access in Alzheimer’s Research & Therapy, enabling broad international access to the results for researchers, clinicians and other stakeholders in the Alzheimer’s field.
Link to the article: https://link.springer.com/article/10.1186/s13195-026-02082-9
For more information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com
About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com